97
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Cardiovascular Events Associated with Antipsychotics in Newly Diagnosed Parkinson’s Disease Patients: A Propensity Score Matched Cohort Study

ORCID Icon
Pages 2975-2987 | Published online: 29 Jun 2021

References

  • Alves M, Caldeira D, Ferro JM, Ferreira JJ. Does Parkinson’s disease increase the risk of cardiovascular events? A systematic review and meta-analysis. Eur J Neurol. 2020;27(2):288–296. doi:10.1111/ene.14076
  • Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Cardiac abnormalities in Parkinson’s disease and Parkinsonism. J Clin Neurosci. 2018;53:1–5. doi:10.1016/j.jocn.2018.04.031
  • McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17(1):126. doi:10.1186/s12883-017-0904-4
  • Yang YW, Hsieh TF, Li CI, et al. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore). 2017;96(3):e5921. doi:10.1097/MD.0000000000005921
  • Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29–38. doi:10.1056/NEJMoa062222
  • Crispo JAG, Willis AW, Thibault DP, et al. Associations between cardiovascular events and nonergot dopamine agonists in parkinson’s disease movement disorders clinical practice. Movement Disorders Clin Practice. 2016;3(3):257–267. doi:10.1002/mdc3.12286
  • Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf. 2012;4:93. doi:10.2147/DHPS.S28804
  • Rotella F, Cassioli E, Calderani E, et al. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2020;32:56–65. doi:10.1016/j.euroneuro.2019.12.118
  • Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017. doi:10.1038/nrn.2017.62
  • Marras C, Kopp A, Qiu F, et al. Antipsychotic use in older adults with Parkinson’s disease. Mov Disord. 2007;22(3):319–323. doi:10.1002/mds.21192
  • Wang MT, Lian PW, Yeh CB, Yen CH, Ma KH, Chan AL. Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson’s disease. Mov Disord. 2011;26(9):1663–1669. doi:10.1002/mds.23719
  • Food and Drug Administration (FDA) Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. Department of Health and Human Services, U.S. Government; 2005. Available from: www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171.htm. Accessed June 2.
  • Food and Drug Administration (FDA). Information for Healthcare Professionals—antipsychotics. Department of Health and Human Services, U.S. Government; 2008. Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm. Accessed June 2.
  • Weintraub D, Chiang C, Kim HM, et al. Antipsychotic use and physical morbidity in parkinson disease. Am j Geriatric Psychiatry. 2017;25(7):697–705. doi:10.1016/j.jagp.2017.01.076
  • Weintraub D, Chiang C, Kim HM, et al. Association of antipsychotic use with mortality risk in patients with parkinson disease. JAMA Neurol. 2016;73(5):535–541. doi:10.1001/jamaneurol.2016.0031
  • Ballard C, Isaacson S, Mills R, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with parkinson disease psychosis. J Am Med Dir Assoc. 2015;16(10):898e1–7. doi:10.1016/j.jamda.2015.06.021
  • Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Safety. 2017;40(9):771–781. doi:10.1007/s40264-017-0543-0
  • Barbui C, Gastaldon C, Papola D, Ostuzzi G. Antipsychotic drug exposure and risk of myocardial infarction. Epidemiol Psychiatr Sci. 2017;26(1):18–21. doi:10.1017/S204579601600086X
  • Papola D, Ostuzzi G, Gastaldon C, et al. Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. Acta Psychiatr Scand. 2019;140(3):227–243. doi:10.1111/acps.13066
  • Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1–3):91–100. doi:10.1016/j.schres.2006.08.017
  • Lin ST, Chen CC, Tsang HY, et al. Association between antipsychotic use and risk of acute myocardial infarction: a nationwide case-crossover study. Circulation. 2014;130(3):235–243. doi:10.1161/CIRCULATIONAHA.114.008779
  • Malekizadeh Y, Williams G, Kelson M, et al. Whole transcriptome in silico screening implicates cardiovascular and infectious disease in the mechanism of action underlying atypical antipsychotic side effects. Alzheimers Dement (N Y). 2020;6(1):e12078. doi:10.1002/trc2.12078
  • Beauchemin M, Geguchadze R, Guntur AR, et al. Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: risperidone alters the cardiac proteomic signature in mice. Pharmacol Res. 2020;152:104589. doi:10.1016/j.phrs.2019.104589
  • May M, Beauchemin M, Vary C, Barlow D, Houseknecht KL. The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice. PLoS One. 2019;14(6):e0218937. doi:10.1371/journal.pone.0218937
  • Nielsen R-E, Lolk A, Rodrigo-Domingo M, Valentin J-B, Andersen K. Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer’s dementia. Eur Psychiatry. 2017;42:14–23. doi:10.1016/j.eurpsy.2016.11.013
  • Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169(9):900–906. doi:10.1176/appi.ajp.2012.12030342
  • Jones KHFD, Lyons RA. The SAIL databank: 10 years of spearheading data privacy and research utility, 2007–2017. University S; 2017.
  • Robinson D, Schulz E, Brown P, Price C. Updating the Read Codes: user-interactive maintenance of a dynamic clinical vocabulary. J Am Med Inform Assoc. 1997;4(6):465–472. doi:10.1136/jamia.1997.0040465
  • Parkinson’s UK. The prevalence and incidence of Parkinson’s in the UK. Parkinson’s UK; 2017. Available from: https://www.parkinsons.org.uk/sites/default/files/2018-01/Prevalence%20%20Incidence%20Report%20Latest_Public_2.pdf. Accessed January 25, 2018.
  • Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165(16):1882–1888. doi:10.1001/archinte.165.16.1882
  • Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–1022. doi:10.1093/aje/kwg068
  • Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006;5(4):355–363. doi:10.1016/S1474-4422(06)70411-2
  • Faustino PR, Duarte GS, Chendo I, et al. Risk of developing parkinson disease in bipolar disorder: a systematic review and meta-analysis. JAMA Neurol. 2020;77(2):192–198. doi:10.1001/jamaneurol.2019.3446
  • Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786
  • Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature. JRSM Cardiovasc Dis. 2017;6:2048004016687211. doi:10.1177/2048004016687211
  • Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123–55. doi:10.1161/CIR.0000000000000404
  • Nezafati MH, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: a narrative review. ARYA Atheroscler. 2015;11(5):295–304.
  • McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098. doi:10.1371/journal.pmed.1001098
  • Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. John Wiley & Sons; 2011.
  • Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710–718. doi:10.1093/aje/kwk052
  • Vrettos I, Voukelatou P, Katsoras A, Theotoka D, Kalliakmanis A. Diseases linked to polypharmacy in elderly patients. Curr Gerontol Geriatr Res. 2017;2017:4276047. doi:10.1155/2017/4276047
  • Csoti I, Herbst H, Urban P, Woitalla D, Wullner U. Polypharmacy in Parkinson’s disease: risks and benefits with little evidence. J Neural Transm (Vienna). 2019;126(7):871–878. doi:10.1007/s00702-019-02026-8
  • Marras C, Austin PC, Bronskill SE, Diong C, Rochon PA. Antipsychotic drug dispensing in older adults with parkinsonism. Am j Geriatric Psychiatry. 2018;26(12):1244–1257. doi:10.1016/j.jagp.2018.08.003
  • Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology. 2007;32(8):1715–1726. doi:10.1038/sj.npp.1301305
  • Rogers G, Davies D, Pink J, Cooper P. Parkinson’s disease: summary of updated NICE guidance. BMJ. 2017;358:j1951. doi:10.1136/bmj.j1951
  • Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010;75(14):1270–1276. doi:10.1212/WNL.0b013e3181f61311
  • Jackson JW, VanderWeele TJ, Blacker D, Schneeweiss S. Mediators of first- versus second-generation antipsychotic-related mortality in older adults. Epidemiology. 2015;26(5):700–709. doi:10.1097/EDE.0000000000000321
  • Zhang H, Wang L, Fan Y, et al. Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2019;15:2137–2149. doi:10.2147/NDT.S201029
  • Patel RS, Bhela J, Tahir M, Pisati SR, Hossain S. Pimavanserin in parkinson’s disease-induced psychosis: a literature review. Cureus. 2019;11(7):e5257. doi:10.7759/cureus.5257
  • Sprenger F, Poewe W. Management of motor and non-motor symptoms in Parkinson’s disease. CNS Drugs. 2013;27(4):259–272. doi:10.1007/s40263-013-0053-2